C7938
2-氯-N6-环戊基腺苷
adenosine receptor agonist
别名:
CCPA
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H20ClN5O4
化学文摘社编号:
分子量:
369.80
NACRES:
NA.51
PubChem Substance ID:
UNSPSC Code:
41106305
MDL number:
Assay:
≥98% (TLC)
Form:
powder
Solubility:
methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
Storage temp.:
2-8°C
产品名称
2-氯-N6-环戊基腺苷, adenosine receptor agonist
InChI
1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)/t8-,10-,11-,14-/m1/s1
SMILES string
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(NC4CCCC4)nc(Cl)nc23
InChI key
XSMYYYQVWPZWIZ-IDTAVKCVSA-N
assay
≥98% (TLC)
form
powder
solubility
methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
storage temp.
2-8°C
Quality Level
Gene Information
human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140)
rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
Application
2-氯-N6-环戊基腺苷（CCPA）是一种具有高选择性的A1腺苷受体激动剂。CCPA通常与其他腺苷受体激动剂和拮抗剂一起使用，以平衡A(1)、A(2A)和A(3)受体的功能。这些药物包括DPCPX（A(1) 受体拮抗剂）、4-(2-[7-氨基-2-(2-呋喃基)[1,2,4]三唑[2,3-α][1,3,5]三嗪-5-基氨基]乙基)苯酚（A(2A)受体拮抗剂）和4-[2-[[6-氨基-9-(N-乙基-β-D-核呋喃核糖酰胺基)-9H-嘌呤-2-基]氨基]乙基]苯丙酸盐酸盐（A(2A) 受体激动剂）和Cl-IB-MECA（A(3)受体激动剂）。
Biochem/physiol Actions
具有高选择性的A1腺苷受体激动剂：据报道，A1受体的选择性是A2受体的10,000倍。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Iftikhar Ahmad et al.
Scientific reports, 10(1), 364-364 (2020-01-17)
Real world complex networks are indirect representation of complex systems. They grow over time. These networks are fragmented and raucous in practice. An important concern about complex network is link prediction. Link prediction aims to determine the possibility of probable
N L D Smith et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 20(8), O480-O488 (2013-11-28)
Chronic cavitary pulmonary aspergillosis (CCPA) is a progressive lung condition with a 10-30% annual mortality. Although overtly immunocompetent, some immunogenetic defect in patients is likely. To investigate a possible immunogenetic defect in CCPA, we analysed biologically plausible candidate genes in
Romeo Romagnoli et al.
Journal of medicinal chemistry, 51(18), 5875-5879 (2008-08-30)
The synthesis and evaluation of a series of 2-amino-3-(4-chlorobenzoyl)-4-[4-(alkyl/aryl)piperazin-yl]thiophene derivatives as allosteric enhancers of the A 1-adenosine receptor are described. The nature of substituents on the phenyl ring tethered to the piperazine seem to exert a fundamental influence on the
Mary Clare Luca et al.
Clinical hemorheology and microcirculation, 49(1-4), 287-293 (2012-01-05)
Despite decades of research and thousands of experimental publications, acute preconditioning strategies have yet to be implemented in clinical practice. While some have attributed this to a failure of the experimental studies to mimic the clinical environment, others have suggested
Ruzanna Shkhyan et al.
Journal of molecular medicine (Berlin, Germany), 96(10), 1049-1060 (2018-08-09)
Osteoarthritis (OA), the most common form of arthritis, is characterized by inflammation of joints and cartilage degradation leading to disability, discomfort, severe pain, inflammation, and stiffness of the joint. It has been shown that adenosine, a purine nucleoside composed of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持